FDA declined to appeal a court ruling invalidating its 2024 LDT rule, concluding its push to expand regulatory control over lab-developed tests.
In Wuhan Healthgen Biotechnology Corp. v. U.S. ITC, the Federal Circuit upheld an ITC ruling that Ventria Bioscience met the domestic industry requirement despite a modest investment in a patented bio
A Delaware court has ruled in favor of a biotech startup in a high-stakes lawsuit involving allegations of misappropriated trade secrets related to cancer treatment.
Examining the allegations against Valeant Pharma for using fraudulently obtained patent rights to overcharge the U.S. government.
